Nanologica Publishes supplementary Prospectus in Connection with Rights Issue
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR IN ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL, SUBJECT TO LEGAL RESTRICTIONS OR WOULD REQUIRE REGISTRATION OR OTHER MEASURES.
Nanologica AB (publ) (”Nanologica” or the “Company”) publishes a supplement (the “Supplementary Prospectus”) to the prospectus approved by the Swedish Financial Supervisory Authority and published on October 26, 2024 (the “Prospectus”) regarding the ongoing rights issue (the “Rights Issue”). The Supplement Prospectus is part of and should be read together with the Prospectus.
The Supplementary Prospectus has been prepared due to the fact that the Company, following the publication of the Prospectus, through a press release on October 4, 2024 announced that the Company had reveiced an order for its silica-based purification media NLAB Saga® from a customer in China at a value of SEK 1.9 million. Considering the size of the order, in relation to the Company’s turnover, the Company believes that the order is a circumstance that may affect the assessment of the offering in the Prospectus. The press release has been published in its entirety on the Company’s website www.nanologica.com.
The Supplementary Prospectus which today October 8, 2024 has been approved by the Swedish Financial Supervisory Authority, forms part of and should be read toghether with the Prospectus. The Prospectus and the Supplementary Prospectus are available on the Company’s website (www.nanologica.com), Bergs Securities’ website (www.bergssecurities.se), and the Swedish Financial Supervisory Authority’s website (www.fi.se).
For complete terms and conditions and other information about the Rights Issue, please refer to the Prospectus and the Supplementary Prospectus.
Advisors
Nanologica has engaged Redeye AB as Joint Bookrunner, Bergs Securities AB as Joint Bookrunner and issuing agent, and Advokatfirman Lindahl KB as legal advisor in connection with the Rights Issue.